Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes
Bandaranayake T, Radcliffe C, Cvercko M, Golden M, Hao R. Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes. JAC-Antimicrobial Resistance 2024, 6: dlae174. PMID: 39493938, PMCID: PMC11524893, DOI: 10.1093/jacamr/dlae174.Peer-Reviewed Original ResearchDose of oritavancinInfective endocarditisTreatment of acute bacterial skinBacterial infectionsLipoglycopeptide antibacterial agentTertiary care medical centreAcute bacterial skinGram-positive bacterial infectionsInvasive bacterial infectionsTreatment failure rateNinety-five adult patientsSoft tissue infectionsProsthetic joint infectionGram-positive organismsBacterial skinDrug discontinuationTissue infectionsRetrospective studyAdult patientsClinical outcomesAdverse eventsOritavancinOff-labelJoint infectionTreat infectionsSevere Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults
Legakis L, Nguyen D, Bandaranayake T. Severe Clinical Outcomes Due to Human Adenoviral Respiratory Infections in Hospitalized Immunocompetent Adults. Infectious Diseases In Clinical Practice 2024, 32: e1412. DOI: 10.1097/ipc.0000000000001412.Peer-Reviewed Original ResearchSevere adenoviral infectionAdenoviral infectionImmunocompetent patientsClinical outcomesSmoking historyPulmonary diseaseRisk factorsSevere diseaseAdenoviral respiratory infectionUpper respiratory tract infectionRespiratory viral panelAbsence of feverAdult immunocompetent patientsExtracorporeal membrane oxygenationRespiratory tract infectionsSevere clinical outcomesChronic obstructive pulmonary diseasePresence of coinfectionObstructive pulmonary diseasePotential risk factorsCritical careImmunocompetent adultsImmunocompromised patientsImmunocompetent hostsTract infections